Pharming Group (NASDAQ:PHAR) Posts Earnings Results, Misses Estimates By $0.02 EPS

Pharming Group (NASDAQ:PHAR) posted its earnings results on Thursday. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02), Zacks reports. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Pharming Group updated its FY 2025 guidance to EPS.

Pharming Group Price Performance

Shares of NASDAQ PHAR opened at $8.77 on Friday. Pharming Group has a twelve month low of $6.65 and a twelve month high of $11.80. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $596.63 million, a price-to-earnings ratio of -33.73 and a beta of -0.10. The firm has a 50-day moving average of $8.99 and a two-hundred day moving average of $8.58.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PHAR shares. HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Friday. Oppenheimer boosted their target price on shares of Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Jefferies Financial Group started coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 target price for the company.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.